Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sonedenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 17/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 14/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sonedenoson SCHEMBL24838606 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL13010610 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL29379294 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL23898701 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| Sonedenoson SCHEMBL1094594 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111704 | 0.93 | ADORA2A (0.88) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111713 | 0.93 | ADORA2A (0.88) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL14903077 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL8111385 | 0.92 | ADORA2A (0.86) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL2294338 | 0.92 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491928-A2 | Therapeutic agent for vitiligo and method of accelerating pigmentation | The University of Tokyo (JP) | 2012-08-29 | — | — | EP | claimed |
| US-8153781-B2 | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-10 | — | — | US | claimed |
| US-20110144027-A1 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING WOUND HEALING | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2011-06-16 | — | — | US | claimed |
| US-20100324279-A1 | CRYSTAL FORMS OF 2-[2-(4-CHLOROPHENYL)ETHOXY]ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2010-12-23 | — | — | US | claimed |
| EP-2225255-A1 | CRYSTAL FORMS OF 2-[2-(4-CHLOROPHENYL)ETHOXY]ADENOSINE | King Pharmaceuticals Research and Development Inc. (US) | 2010-09-08 | — | — | EP | claimed |
| US-20100222275-A1 | THERAPEUTIC AGENT FOR VITILIGO AND METHOD OF ACCELERATING PIGMENTATION | MARUHO CO., LTD (JP) | 2010-09-02 | — | — | US | claimed |
| EP-2198887-A1 | THERAPEUTIC AGENT FOR LEUKODERMA AND METHOD FOR ACCELERATION OF PIGMENTATION | The University of Tokyo (JP) | 2010-06-23 | — | — | EP | claimed |
| EP-2170401-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009085909-A1 | CRYSTAL FORMS OF 2-[2-(4-CHLOROPHENYL)ETHOXY]ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA (US) | 2009-01-08 | — | — | US | claimed |
| WO-2009006046-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | claimed |
| EP-2001489-A2 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING WOUND HEALING | King Pharmaceuticals Research and Development Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| US-7342003-B2 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-03-11 | — | — | US | claimed |
| WO-2007123740-A2 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING WOUND HEALING | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| EP-1446413-A4 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RES & DEV (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070232561-A1 | Pharmaceutical compositions for promoting wound healing | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-04 | — | — | US | claimed |
| US-6951932-B2 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-10-04 | — | — | US | claimed |
| EP-1446413-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | King Pharmaceuticals Research and Development Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003035662-A1 | SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199686-A1 | Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines | AMPD2, ADAR, ADA | ADORA2A 16/4885ADORA2B 58/4885ADORA1 69/4885 |
| US-20100222275-A1 | THERAPEUTIC AGENT FOR VITILIGO AND METHOD OF ACCELERATING PIGMENTATION | TYR, PRKACG, MC1R | ADORA2A 1496/4885ADORA2B 2309/4885ADORA1 2423/4885 |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 9/4885ADORA1 1/4885 |
| US-20100324279-A1 | CRYSTAL FORMS OF 2-[2-(4-CHLOROPHENYL)ETHOXY]ADENOSINE | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.